FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174168369> ?p ?o ?g. }

• W3174168369 abstract "Objective: This randomized, multicenter trial was designed to evaluate the efficacy of cytokine-induced killer (CIK) cell immunotherapy combination with chemotherapy in patients with advanced squamous non-small-cell lung cancer (NSCLC). Patients and Methods: In this phase II trial, 90 patients with untreated, stage IIIB/IV squamous NSCLC were randomized to autologous CIK cell immunotherapy plus gemcitabine and cisplatin (CIK-CT group, n = 45), or gemcitabine and cisplatin (CT group, n = 45). The primary endpoint was progression-free survival (PFS) evaluated by Kaplan–Meier analyses and treatment hazard ratios (HRs) with the Cox proportional hazards model. Results: After a median follow-up of 29.3 months, the median PFS was 8.7 months (95% CI, 7.1 to 10.3) in the CIK-CT group and 4.0 months (95% CI, 3.1 to 5.0) in the CT group (HR, 0.26; 95% CI, 0.16 to 0.43; P < .001). The median OS was 21.0 months (95% CI, 17.8 to 24.2) in the CIK-CT group and 10.3 months (95% CI, 7.9 to 12.1) in the CT group (HR, 0.22; 95% CI, 0.13 to 0.40; P < .001). The objective response rate was 62.2% (95% CI, 47.9% to 76.5%) in the CIK-CT group and 31.1% (95% CI, 17.4% to 44.8%) in the CT group ( P < .001). The adverse events of grade 3 or higher were 28.9% (13/45) and 42.2% (19/45) in the CIK-CT group and CT group, respectively. Conclusions: These data suggested that CIK cell immunotherapy could improve the efficacy of chemotherapy in patients with previously untreated, advanced squamous NSCLC. A large sample, multi-center randomized, phase III trial is being carried out in our hospital to further validate these findings. Trial Registration: This trial is registered as an international standard randomized trial with ClinicalTrials.gov Identifier: NCT01631357.Funding Statement: Supported by the National Key Technologies R&D Program of China grant Awards No. 2015BAI12B12 (to Xiubao Ren) and 2018YFC1313400 (to Jianchuan Xia), by the National Natural Science Foundation of China grants Awards No. 81572913 and 81872487 (to Liang Liu).Declaration of Interests: The authors reported no potential conflicts of interest.Ethics Approval Statement This study was approved by the State Food and Drug Administration of China (2006L01023), by the National Key Technologies R&D Program of China (2015BAI12B12), and by the Ethical Committee of Cancer Hospital of Tianjin Medical University, according to the guidelines of the Declaration of Helsinki. Informed consent was obtained from all subjects." @default.
• W3174168369 created "2021-07-05" @default.
• W3174168369 creator A5001547762 @default.
• W3174168369 creator A5003226007 @default.
• W3174168369 creator A5006800281 @default.
• W3174168369 creator A5008367011 @default.
• W3174168369 creator A5009017304 @default.
• W3174168369 creator A5013041561 @default.
• W3174168369 creator A5019708695 @default.
• W3174168369 creator A5024327669 @default.
• W3174168369 creator A5024406300 @default.
• W3174168369 creator A5025751238 @default.
• W3174168369 creator A5026067406 @default.
• W3174168369 creator A5027934348 @default.
• W3174168369 creator A5031523854 @default.
• W3174168369 creator A5033668453 @default.
• W3174168369 creator A5037425711 @default.
• W3174168369 creator A5042394520 @default.
• W3174168369 creator A5043256385 @default.
• W3174168369 creator A5045162177 @default.
• W3174168369 creator A5047175539 @default.
• W3174168369 creator A5048132911 @default.
• W3174168369 creator A5051086772 @default.
• W3174168369 creator A5063983172 @default.
• W3174168369 creator A5065859286 @default.
• W3174168369 creator A5068028253 @default.
• W3174168369 creator A5068181075 @default.
• W3174168369 creator A5068348950 @default.
• W3174168369 creator A5075372820 @default.
• W3174168369 creator A5077880789 @default.
• W3174168369 creator A5080592885 @default.
• W3174168369 creator A5085018290 @default.
• W3174168369 creator A5086902044 @default.
• W3174168369 date "2020-01-01" @default.
• W3174168369 modified "2023-10-12" @default.
• W3174168369 title "Randomized, Multicenter, Open-Label Trial of Autologous Cytokine-Induced Killer Cell Immunotherapy Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer" @default.
• W3174168369 doi "https://doi.org/10.2139/ssrn.3537101" @default.
• W3174168369 hasPublicationYear "2020" @default.
• W3174168369 type Work @default.
• W3174168369 sameAs 3174168369 @default.
• W3174168369 citedByCount "0" @default.
• W3174168369 crossrefType "journal-article" @default.
• W3174168369 hasAuthorship W3174168369A5001547762 @default.
• W3174168369 hasAuthorship W3174168369A5003226007 @default.
• W3174168369 hasAuthorship W3174168369A5006800281 @default.
• W3174168369 hasAuthorship W3174168369A5008367011 @default.
• W3174168369 hasAuthorship W3174168369A5009017304 @default.
• W3174168369 hasAuthorship W3174168369A5013041561 @default.
• W3174168369 hasAuthorship W3174168369A5019708695 @default.
• W3174168369 hasAuthorship W3174168369A5024327669 @default.
• W3174168369 hasAuthorship W3174168369A5024406300 @default.
• W3174168369 hasAuthorship W3174168369A5025751238 @default.
• W3174168369 hasAuthorship W3174168369A5026067406 @default.
• W3174168369 hasAuthorship W3174168369A5027934348 @default.
• W3174168369 hasAuthorship W3174168369A5031523854 @default.
• W3174168369 hasAuthorship W3174168369A5033668453 @default.
• W3174168369 hasAuthorship W3174168369A5037425711 @default.
• W3174168369 hasAuthorship W3174168369A5042394520 @default.
• W3174168369 hasAuthorship W3174168369A5043256385 @default.
• W3174168369 hasAuthorship W3174168369A5045162177 @default.
• W3174168369 hasAuthorship W3174168369A5047175539 @default.
• W3174168369 hasAuthorship W3174168369A5048132911 @default.
• W3174168369 hasAuthorship W3174168369A5051086772 @default.
• W3174168369 hasAuthorship W3174168369A5063983172 @default.
• W3174168369 hasAuthorship W3174168369A5065859286 @default.
• W3174168369 hasAuthorship W3174168369A5068028253 @default.
• W3174168369 hasAuthorship W3174168369A5068181075 @default.
• W3174168369 hasAuthorship W3174168369A5068348950 @default.
• W3174168369 hasAuthorship W3174168369A5075372820 @default.
• W3174168369 hasAuthorship W3174168369A5077880789 @default.
• W3174168369 hasAuthorship W3174168369A5080592885 @default.
• W3174168369 hasAuthorship W3174168369A5085018290 @default.
• W3174168369 hasAuthorship W3174168369A5086902044 @default.
• W3174168369 hasConcept C114684123 @default.
• W3174168369 hasConcept C121608353 @default.
• W3174168369 hasConcept C126322002 @default.
• W3174168369 hasConcept C143998085 @default.
• W3174168369 hasConcept C147483822 @default.
• W3174168369 hasConcept C167672396 @default.
• W3174168369 hasConcept C168563851 @default.
• W3174168369 hasConcept C197934379 @default.
• W3174168369 hasConcept C203014093 @default.
• W3174168369 hasConcept C203092338 @default.
• W3174168369 hasConcept C207103383 @default.
• W3174168369 hasConcept C2776256026 @default.
• W3174168369 hasConcept C2776694085 @default.
• W3174168369 hasConcept C2777701055 @default.
• W3174168369 hasConcept C2779109515 @default.
• W3174168369 hasConcept C2780258809 @default.
• W3174168369 hasConcept C44249647 @default.
• W3174168369 hasConcept C71924100 @default.
• W3174168369 hasConcept C90924648 @default.
• W3174168369 hasConceptScore W3174168369C114684123 @default.
• W3174168369 hasConceptScore W3174168369C121608353 @default.
• W3174168369 hasConceptScore W3174168369C126322002 @default.
• W3174168369 hasConceptScore W3174168369C143998085 @default.
• W3174168369 hasConceptScore W3174168369C147483822 @default.
• W3174168369 hasConceptScore W3174168369C167672396 @default.
• W3174168369 hasConceptScore W3174168369C168563851 @default.
• W3174168369 hasConceptScore W3174168369C197934379 @default.

• next